[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20043829L - Fremgangsmate for desolvatisering av solvater av atorvastatin-hemikalsium og atorvastatin-hemikalsium som i det vesentlige er fritt for organisk losemiddel - Google Patents

Fremgangsmate for desolvatisering av solvater av atorvastatin-hemikalsium og atorvastatin-hemikalsium som i det vesentlige er fritt for organisk losemiddel

Info

Publication number
NO20043829L
NO20043829L NO20043829A NO20043829A NO20043829L NO 20043829 L NO20043829 L NO 20043829L NO 20043829 A NO20043829 A NO 20043829A NO 20043829 A NO20043829 A NO 20043829A NO 20043829 L NO20043829 L NO 20043829L
Authority
NO
Norway
Prior art keywords
hemicalsium
atorvastatin
organic solvent
essentially free
desolvating
Prior art date
Application number
NO20043829A
Other languages
English (en)
Inventor
Judith Aronhime
Dalia Maidan-Hanoch
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NO20043829L publication Critical patent/NO20043829L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/04Calcium compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • C07D207/402,5-Pyrrolidine-diones
    • C07D207/4162,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20043829A 2002-02-19 2004-09-13 Fremgangsmate for desolvatisering av solvater av atorvastatin-hemikalsium og atorvastatin-hemikalsium som i det vesentlige er fritt for organisk losemiddel NO20043829L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35849702P 2002-02-19 2002-02-19
PCT/US2003/005216 WO2003070665A2 (en) 2002-02-19 2003-02-19 Desolvating solvates of atorvastatin hemi-calcium

Publications (1)

Publication Number Publication Date
NO20043829L true NO20043829L (no) 2004-09-13

Family

ID=27757749

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043829A NO20043829L (no) 2002-02-19 2004-09-13 Fremgangsmate for desolvatisering av solvater av atorvastatin-hemikalsium og atorvastatin-hemikalsium som i det vesentlige er fritt for organisk losemiddel

Country Status (15)

Country Link
US (2) US7122681B2 (no)
EP (1) EP1465901A4 (no)
JP (4) JP4422488B2 (no)
KR (3) KR20040086397A (no)
CN (1) CN100379723C (no)
AU (1) AU2003213171A1 (no)
CA (1) CA2475123A1 (no)
HR (1) HRP20040767A2 (no)
IL (1) IL163594A0 (no)
IS (1) IS7407A (no)
MX (1) MXPA04007995A (no)
NO (1) NO20043829L (no)
PL (1) PL372241A1 (no)
WO (1) WO2003070665A2 (no)
ZA (1) ZA200406229B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US8044086B2 (en) * 2004-07-16 2011-10-25 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
EP1711464A2 (en) * 2004-07-22 2006-10-18 Teva Pharmaceutical Industries Ltd Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation
US7456170B2 (en) * 2004-08-25 2008-11-25 Pfizer Inc. Triazolobenzodiazepines and their use as vasopressin antagonists
WO2006039441A2 (en) * 2004-09-30 2006-04-13 Dr. Reddy's Laboratories Ltd. Amorphous atorvastatin calcium
SK288276B6 (sk) * 2005-04-08 2015-06-02 Egis Gyógyszergyár, Nyilvánosan Működő Részvénytársaság Spôsob prípravy kryštalickej polymorfnej formy hemivápenatej soli atorvastatínu
MX2007014329A (es) * 2005-12-13 2008-03-19 Teva Pharma Forma cristalina de hemi-calcio de atorvastatina y procesos para la preparacion de ella.
US20070265456A1 (en) * 2006-05-09 2007-11-15 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IT1390848B1 (it) * 2008-07-31 2011-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
US11261183B2 (en) * 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
CN110678456B (zh) 2017-05-23 2023-05-02 H.隆德贝克有限公司 吡唑magl抑制剂
JOP20190267A1 (ar) * 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US444129A (en) * 1891-01-06 Henry l
US4444129A (en) 1982-11-05 1984-04-24 Lecorp Method of drying fine coal particles
DE3306250A1 (de) * 1983-02-23 1984-08-23 Basf Ag, 6700 Ludwigshafen Sphaerische einkristalle fuer pharmazeutische zwecke
JPS59167676A (ja) 1983-03-11 1984-09-21 株式会社 大川原製作所 多室型流動層乾燥機
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
IL128864A (en) * 1995-07-17 2007-10-31 Warner Lambert Co Atorostatin II form crystals and its hydrates, methods of preparation and pharmaceutical preparations containing it
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
WO2001036384A1 (en) 1999-11-17 2001-05-25 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
DE60026737T2 (de) 1999-12-17 2006-09-21 Pfizer Science And Technology Ireland Ltd., Dun Laoghaire Verfahren zur herstellung von kristallin atorvastin kalcium
MXPA02004078A (es) 1999-12-17 2002-10-11 Warner Lambert Res & Dev Un proceso a escala industrial para producir sal de hemi calcio de trihidrato de atorvastatin cristalino.
CN1535139A (zh) * 2000-11-03 2004-10-06 ������ҩ��ҵ���޹�˾ 阿伐他丁半钙形式ⅶ
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
AU2002224952B2 (en) 2000-12-27 2007-04-05 Teva Pharmaceutical Industries Ltd. Crystalline forms of atorvastatin
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
IN190564B (no) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
CA2450111C (en) * 2001-06-29 2006-02-07 Warner-Lambert Company Llc Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
BR0211488A (pt) 2001-07-30 2004-08-17 Reddys Lab Ltd Dr Formas cristalinas vi e vii de atorvastina cálcica
EP1572638A4 (en) 2001-08-31 2010-05-05 Morepen Lab Ltd IMPROVED PROCESS FOR THE PREPARATION OF AMORPHOUS CALCIUM ATORVASTATIN SALT (2: 1)
EP1480950A4 (en) 2002-02-15 2005-05-18 Teva Pharma NOVEL HEMI-CALCIUM CRYSTALLINE FORMS OF ATORVASTATIN AND METHODS FOR THEIR PREPARATION, AS WELL AS NEW METHODS FOR THE PREPARATION OF FORORVASTATIN HEMI-CALCIUM FORMS I, VIII AND IX

Also Published As

Publication number Publication date
US7122681B2 (en) 2006-10-17
PL372241A1 (en) 2005-07-11
JP4422488B2 (ja) 2010-02-24
KR20090045420A (ko) 2009-05-07
CN100379723C (zh) 2008-04-09
JP2009143957A (ja) 2009-07-02
WO2003070665A3 (en) 2004-02-12
WO2003070665A2 (en) 2003-08-28
IS7407A (is) 2004-08-17
KR20040086397A (ko) 2004-10-08
KR20090045419A (ko) 2009-05-07
US20070027328A1 (en) 2007-02-01
JP2005523285A (ja) 2005-08-04
CN1633439A (zh) 2005-06-29
EP1465901A2 (en) 2004-10-13
CA2475123A1 (en) 2003-08-28
JP2009235100A (ja) 2009-10-15
JP2013136630A (ja) 2013-07-11
IL163594A0 (en) 2005-12-18
HRP20040767A2 (en) 2004-12-31
EP1465901A4 (en) 2006-02-01
AU2003213171A1 (en) 2003-09-09
ZA200406229B (en) 2006-06-28
US20030216584A1 (en) 2003-11-20
MXPA04007995A (es) 2004-11-26

Similar Documents

Publication Publication Date Title
NO20043829L (no) Fremgangsmate for desolvatisering av solvater av atorvastatin-hemikalsium og atorvastatin-hemikalsium som i det vesentlige er fritt for organisk losemiddel
NO20033560L (no) Fremgangsmåte for spektral balansering av forskjövne seismiske data
ATE375336T1 (de) Triazolderivate als inhibitoren von11-beta- hydroxysteroid-dehydrogenase-1
ATE398105T1 (de) Carbonylamino- derivativate als neue inhibitoren von histone deacetylase
DE60321808D1 (de) Flavon derivate als inhibitoren von cyclin-abhängigen kinasen
DK1644384T3 (da) Fremgangsmåde og mellemprodukter til syntese af entecavir
NO20033491D0 (no) Heterocykliske inhibitorer av ERK2 og anvendelser derav
DE60221875D1 (de) 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren
NO20024921D0 (no) Kombinasjon av organiske forbindelser
DK1657246T3 (da) Fremgangsmåde til forbedring af renhed og udbytte af sucralose
NO20024920L (no) Kombinasjon av organiske forbindelser
NO20045220L (no) Heterocykliske inhibitorer for kinaser
NO20043907L (no) Partielle og fullstendige agonister av A1-adenosinreseptorer
NO20015274L (no) ACE-2 inhiberende forbindelser og fremgangsmåter for anvendelse derav
HRP20060124A2 (en) Process for the preparation of n-amino substituted heterocyclic compounds
IS8470A (is) Notkun lífrænna efnasambanda
DE60332036D1 (de) Einteilige hand-airbrush
EA200300925A1 (ru) Новый способ промышленного синтеза ранелата стронция и его гидратов
ITMI20021391A1 (it) Nitroderivati di inibitori della cicloossigenasi-2
NO20006331D0 (no) Dekomponeringsapparat for organiske halogenforbindelser og fremgangsmåte ved drift derav, og fremgangsmåte ved dekomponering av organiske halogenforbindelser
NO20021823L (no) Behandling av emfysem ved bruk av RAR-selektive retinoidagonister
NO20021750D0 (no) Syntese og anvendelsesmetoder av 9-substituerte guaninderivater
AU2003207342A1 (en) Cleaning device for cleaning of metal strings of musical instruments
DK1487790T3 (da) Renset lasofoxifen og fremgangsmåde til opensning af racemisk lasofoxifen ved omkrystallisering
DE60308187D1 (de) N-benzyl-3-phenyl-3-heterocyclyl-propionamid-verbindungen als tachykinin rezeptoren antagonisten und/oder als serotoninwiederaufnahme inhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application